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Abstract Medical research has greatly beneited from molecular biology and increasingly 
relies on tools from the “omics” disciplines (mainly genomics, transcriptomics, proteomics and 
metabolomics). The availability of biological samples preserved with high quality standards is a 
sine qua non condition for such studies and their repositories are referred to as biobanks. Biobanks 
support the transportation, storage, preservation, and initial pathological and analytical 
examinations of biospecimens, as well as the protection of relevant information and the comparison 
of clinical and laboratory findings. A biobank facility is one of the most valuable tools the 
academic medicine organizations can offer to their researchers to improve the competitiveness 
of their current and future medical research. it acts as an essential bridge and an effective 
catalyst for research synergies between basic and clinical sciences, and it can be potentiated 
with efforts to raise funds for acquiring and maintaining cutting-edge analytical infrastructure 
to better serve its clinical, pharmaceutical and biotech clients.
1665-5796 © 2014 revista Medicina Universitaria. Facultad de Medicina UANL. Publicado por Elsevier México. Todos 
los derechos reservados.
Merging assistance and research
Medical research beneits more and more from laboratory 
tests which scrutinize patients’ gene pools (genome), sets 
of transcripts (transcriptome), protein patterns (proteome), 
and metabolite proiles (metabolomics). 
When these researches are geared towards discovering 
the causes of the leading health conditions -commonly 
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caused by the effect of multiple and often subtle metabolo-
mic, proteomic,  transcriptomic, or genomic alterations 
(i.e., single nucleotide polymorphisms), it is necessary to 
include in the research protocols a large number of pa-
tients, and to ensure follow-up for several years. This is cru-
cial in an attempt to associate the indings at a molecular 
level with the prognosis of diseases and their response to 
treatment (pharmacogenetics). Therefore, the procure-
ment, preservation, distribution and analytical processing in 
optimal conditions of biospecimens (and their associated 
information), is key in order to maximize their validity, re-
ach and impact.1 
What is a biobank?
The term “biobank” is relatively new. It irst appeared in 
PubMed during the 90´s, yet it was not until the year 2000 
that it became more frequently used.1,2 Biobanks gather, 
store, preserve, process and distribute biological samples 
and all associated data. The importance of sample preserva-
tion has increased in recent years and countries like the 
United Kingdom, the United States of America, China, Swit-
zerland, Estonia, France, Japan, Spain, Norway, and Canada 
rely on biobanks for large-scale sample preservation.3
Biobank beneits
Thanks to standardized and systemic biospecimens and rela-
ted data storage, biobanks are accelerating the develop-
ment of new biotechnological medications, medical devices 
and personalized medicine tests. The combination of clini-
cal, demographic, epidemiologic, and genomic information 
of populations -on occasion entire populations (as DeCODE 
genetics conducts in iceland), allows us to explore and deci-
pher complex interrelations between genes, the environment 
and habits, thus placing us in the path to discover the causes 
of multifactorial complex diseases.3 
Human biospecimens stored in a biobank may be used to:
a. identify and validate therapeutic targets (genes 
and gene products).
b. Discover cellular mechanisms underlying diseases.
c. investigate biomarkers associated with certain sub-
types of diseases.
d. Group patients based on their genetic characteris-
tics and response to treatment, which allows for 
the development of new individualized therapies.
e. Try disease associations with a genetic variation in 
genomes of a certain population and compare it to 
other populations. 
How does a biobank work?
Most of the materials stored in biobanks are specimens deri-
ved from human blood and other tissues, along with the do-
nors’ information. The stored samples correspond to patients 
who, fully informed and voluntarily, decided to donate them 
with the purpose of supporting scientiic research properly 
approved by the research Ethics Committee of the participa- 
ting institutions. Biobanks operate with dual responsibili-
ties; on one hand they have to preserve the biospecimens 
and their respective information; on the other hand they 
are obliged to protect the privacy and conidentiality of 
such information, granting access exclusively to authori-
zed researchers under the applicable institutional guideli-
nes.2,4
Personnel working in biobanks offer the following services:
a. Obtaining a signed consent form including the sto-
rage of biospecimens. 
b. Compiling the necessary information from the do-
nors.
c. Transporting biospecimens in good time and in an 
appropriate manner for their preservation.
d. Codifying all relevant information, guaranteeing 
conidentiality.
Origins of the Biobank of the School of 
Medicine and University Hospital of the 
Universidad Autónoma de Nuevo León (UANL) 
The Department of Biochemistry and Molecular Medicine 
(DBMM) of the UANL’s School of Medicine has been leading 
edge in its country in the study of the molecular biology of 
various diseases. These studies were made possible thanks 
to the collaboration of different departments and services 
of “Dr. José Eleuterio González” University Hospital (HU-
UANL). Among these researches, the irst two gene therapy 
protocols (for prostate and cervical cancer) carried out in 
Latin America stood out over 10 years ago.
Supported by their current infrastructure, the DBMM’s Me-
dical Biotechnology Unit (MBU) has considerable experience 
in large-scale biological sample storage, which was created 
through a research project in collaboration with the State 
Secretary of Health concerning cervical cancer risk factors. 
in 2002 almost 5000 samples from voluntary females were 
gathered for this project. This and subsequent large-sca- 
le biospecimen storage experiences have made evident the 
need to have an institutional biobank.
Gradually, this “pilot biobank” initiated at UBM has been 
supporting more and more projects and theses of the diffe-
rent departments of the UANL’s HU and Faculty of Medicine.
An innovative idea
Because the development of clinical research in our institu-
tion is expanding, the implementation of its biobank is not 
only crucial, but a strategic pillar for the aspirations of ex-
cellence in effective assistance, research and connection 
with pharmaceutical and biotechnological industries. The 
implementation of the institution’s hospital biobanks will 
allow the preservation of valuable samples for subsequent 
analysis. 
Visionary tasks 
The institution began implementing its biobank so that re-
searchers -distributed over 52 different departments- may 
multiply their excellent researches in scientiic and technolo-
gical approaches, meeting international standards (bioethics 
included), with a wider reach and preferably connected to 
multi-center projects of interest in public and private sec-
tors, domestically as well as internationally. 
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The institutional Biobank will include reception, sampling, 
extraction, labs and biomolecules analysis areas, massive low- 
temperature storage refrigeration of biospecimens, and com-
putational infrastructure for sample and data control, etc.
The Biobank project is being subjected to evaluation for 
its possible approval by our institution’s research Ethics 
Committee. Once the Biobank is operating, each researcher 
who requests biological sample preservation there will be 
required to have the corresponding protocol’s approval let-
ter from said Committee as an essential requirement to sto-
re the biological material. 
Contribution to regional and economic 
development
The proposed institutional biobank will bring social beneits; 
having higher quality researches will contribute to the gene-
ration of more and better health in the community, while 
alliances with more pharmaceutical and biotechnological 
industries will contribute to regional and economic develo-
pment.
At the same time, the project will help create a new era 
for clinical research in Latin America, a region that despite 
having become one of the most relevant in the research of 
new medications and medical devices, has not grown to its 
full potential due to the lack of biobanks.
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